Jacobs & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$516K Sell
4,090
-139
-3% -$18.3K 0.04% 95
2026
Q1
$589K Sell
4,229
-33
-0.8% -$4.62K 0.06% 94
2025
Q4
$523K Sell
4,262
-288
-6% -$35K 0.05% 95
2025
Q3
$505K Sell
4,550
-25
-0.5% -$2.84K 0.05% 95
2025
Q2
$507K Sell
4,575
-315
-6% -$33.5K 0.05% 97
2025
Q1
$547K Sell
4,890
-275
-5% -$28.4K 0.06% 96
2024
Q4
$477K Sell
5,165
-580
-10% -$52.2K 0.05% 98
2024
Q3
$481K Sell
5,745
-4,877
-46% -$372K 0.05% 99
2024
Q2
$728K Sell
10,622
-16,640
-61% -$1.11M 0.08% 93
2024
Q1
$2M Buy
27,262
+725
+3% +$55.8K 0.21% 83
2023
Q4
$2.15M Sell
26,537
-784
-3% -$61K 0.24% 84
2023
Q3
$2.05M Buy
27,321
+35
+0.1% +$2.69K 0.26% 85
2023
Q2
$2.1M Buy
27,286
+105
+0.4% +$8.37K 0.25% 85
2023
Q1
$2.25M Buy
27,181
+195
+0.7% +$16.2K 0.28% 82
2022
Q4
$2.32M Buy
26,986
+127
+0.5% +$10.1K 0.3% 80
2022
Q3
$1.66M Buy
26,859
+560
+2% +$35.3K 0.24% 84
2022
Q2
$1.63M Buy
26,299
+775
+3% +$48K 0.22% 84
2022
Q1
$1.52M Buy
25,524
+1,835
+8% +$117K 0.17% 84
2021
Q4
$1.72M Sell
23,689
-4,400
-16% -$303K 0.18% 82
2021
Q3
$1.96M Hold
28,089
0.23% 80
2021
Q2
$1.93M Buy
28,089
+525
+2% +$35.1K 0.22% 80
2021
Q1
$1.78M Sell
27,564
-1,120
-4% -$72.2K 0.22% 79
2020
Q4
$1.67M Buy
28,684
+735
+3% +$44.4K 0.22% 77
2020
Q3
$1.77M Buy
27,949
+5,595
+25% +$388K 0.26% 75
2020
Q2
$1.72M Buy
22,354
+2,100
+10% +$161K 0.28% 76
2020
Q1
$1.51M Sell
20,254
-150
-0.7% -$10.4K 0.29% 76
2019
Q4
$1.32M Sell
20,404
-847
-4% -$55.2K 0.2% 81
2019
Q3
$1.35M Sell
21,251
-2,003
-9% -$131K 0.22% 83
2019
Q2
$1.57M Sell
23,254
-385
-2% -$25.3K 0.25% 84
2019
Q1
$1.54M Sell
23,639
-1,535
-6% -$102K 0.26% 84
2018
Q4
$1.57M Buy
25,174
+44
+0.2% +$3.08K 0.31% 78
2018
Q3
$1.94M Sell
25,130
-2,907
-10% -$220K 0.33% 79
2018
Q2
$1.99M Sell
28,037
-130
-0.5% -$9.18K 0.36% 79
2018
Q1
$2.12M Buy
28,167
+295
+1% +$23.5K 0.39% 77
2017
Q4
$2M Sell
27,872
-200
-0.7% -$15.2K 0.36% 79
2017
Q3
$2.27M Buy
28,072
+2
+0% +$153 0.43% 77
2017
Q2
$1.99M Sell
28,070
-1,892
-6% -$126K 0.39% 78
2017
Q1
$2.04M Sell
29,962
-3,500
-10% -$246K 0.42% 78
2016
Q4
$2.4M Sell
33,462
-626
-2% -$46.5K 0.52% 72
2016
Q3
$2.7M Buy
34,088
+148
+0.4% +$12K 0.6% 67
2016
Q2
$2.83M Buy
33,940
+380
+1% +$33.7K 0.67% 63
2016
Q1
$3.08M Sell
33,560
-292
-0.9% -$26.3K 0.74% 55
2015
Q4
$3.29M Buy
33,852
+1,116
+3% +$116K 0.85% 50
2015
Q3
$3.21M Buy
32,736
+746
+2% +$82.9K 0.85% 48
2015
Q2
$3.75M Buy
31,990
+60
+0.2% +$6.56K 0.94% 48
2015
Q1
$3.13M Buy
31,930
+2,285
+8% +$232K 0.79% 55
2014
Q4
$2.79M Buy
29,645
+1,240
+4% +$128K 0.74% 57
2014
Q3
$3.02M Sell
28,405
-485
-2% -$47.5K 0.86% 54
2014
Q2
$2.4M Buy
28,890
+110
+0.4% +$8.56K 0.69% 62
2014
Q1
$2.04M Sell
28,780
-280
-1% -$22K 0.63% 64
2013
Q4
$2.18M Sell
29,060
-2,365
-8% -$165K 0.7% 60
2013
Q3
$1.98M Sell
31,425
-230
-0.7% -$13.7K 0.69% 59
2013
Q2
$1.62M Buy
+31,655
New +$1.65M 0.59% 66

Other funds holding GILD

Jacobs & Co's GILD Position: Q2 2026 in Review

Jacobs & Co reduced its Gilead Sciences (GILD) stake by 3.3% in Q2 2026, selling an estimated $18.3K and leaving 4,090 shares worth $516K. The position accounts for 0.04% of the portfolio, ranked #95.

Jacobs & Co first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.75M in Q2 2015. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Jacobs & Co held 4,090 shares of Gilead Sciences worth $516K as of Q2 2026.
  • Jacobs & Co sold 139 Gilead Sciences shares in Q2 2026, an estimated $18.3K.
  • Gilead Sciences made up 0.04% of Jacobs & Co's portfolio in Q2 2026, its #95 holding.
  • Jacobs & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Jacobs & Co's Gilead Sciences position peaked at $3.75M in Q2 2015.
  • 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Jacobs & Co's 13F filing for Q2 2026, filed 9 Jul 2026.